{"prompt": "['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', 'masses such as schwannomas and meningiomas that are causing edema or mass', 'effect)', 'b. Severe or unstable angina, myocardial infarction, symptomatic congestive heart', 'failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,', 'cerebrovascular accident including transient ischemic attacks), or clinically', 'significant ventricular arrhythmias within 6 months prior to registration.', 'C. Any condition that in the opinion of the investigator, would preclude participation in', 'this study', '7. Current evidence of any of the following:', 'a. Uncontrolled hypertension', 'b. Gastrointestinal disorder affecting absorption', 'C.', 'Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or', 'other medical condition that would make prednisone/prednisolone (corticosteroid)', 'use contraindicated', 'd. Any condition that in the opinion of the investigator, would preclude participation in', 'this study', '8. The use of drugs known to lower the seizure threshold, including: atypical antipsychotics', '(e.g., clozapine, olanzapine, risperidone, ziprasidone), bupropion, lithium, meperedine,', 'pethidine, phenothiazine antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine),', 'and tricyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine,', 'maprotiline, mirtazapine) (see Appendix C for a more complete list of prohibited concomitant', 'medications).', '9. The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin, erythromycin,', 'diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir,', 'saquinavir, telithromycin, voriconazole, grapefruit juice (or grapefruits) (see Appendix C for a', 'more complete list of prohibited concomitant medications). Note: If a patient is on a strong', 'CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said', 'medication. A two week or 5 half-lives, whichever is longer, washout will be required prior to', 'enrolling on study. Subject may not resume medication while receiving apalutamide.', '10. Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin, rifapentin,', \"phenobarbital, efavirenz, tipranivir, St. John's wort (see Appendix C for a more complete list\", 'of prohibited concomitant medications). Note: If a patient is on a strong CYP3A4 inducer,', 'they can be reconsidered for enrollment if they can safely stop said medication. A two week', 'or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study.', 'Subject may not resume medication while receiving apalutamide.', '11. Any psychological, familial, sociological, or geographical condition that could potentially', 'interfere with compliance with the study protocol and follow-up schedule.', 'Primary Objective: Determine the negative repeat biopsy rate by site directed and systematic', 'prostate biopsy after 90-days of apalutamide.', 'Secondary Objectives:', '1. Determine the rate of exit at 2 years from active surveillance due to pathologic', 'reclassification.', '2. Determine the overall rate of exit at 2 years from active surveillance.', '6', 'Printed on 1/29/2021']['IRB Approved', 'Document Release Date: 02/26/2020', 'CC Protocol Number: 9582', 'PI: Michael T. Schweizer, MD', 'Apalutamide in Active Surveillance patients', 'Protocol Version: 6.0; September 06, 2019', '3. Determine the rate of local treatment (e.g., radical prostatectomy, radiation therapy,', 'brachytherapy) at 2 years and the local treatment free survival.', '4. Determine PSA progression rates and PSA progression free survival (PFS), as defined by', 'the Prostate Cancer Working Group 2 (PCWG2) criteria.', '5. Determine the rate of radiographic disappearance of MRI detectable prostate cancer', 'following treatment (only in patients with a baseline nodule that is PIRADS 3 or more and', '>5mm).', '6. Investigate the safety of apalutamide in men undergoing active surveillance.', 'a. Safety will be evaluated by the incidence, severity, duration, causality, seriousness,', 'and type(s) of adverse events as assessed by the revised National Cancer Institute', 'Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03', 'published 14 June 2010.', '7. Track quality of life utilizing the FACT-P and SF36 surveys for each cohort.', '8. Exploratory biomarker Assessment. Examples of these may include, but are not limited to:', 'assessment for genomic PTEN loss via fluorescence in situ hybridization (FISH), PTEN', 'immunohistochemistry (IHC), assessment for alteration in MYC/chromosome 8q24 via FISH', 'and tumor mRNA expression profiling/risk classification (e.g., Decipher, Oncotype DX', 'Prostate Cancer Assay, or RNA-seq).', 'Primary Endpoint: Negative (i.e., no residual carcinoma) site directed and systematic prostate', 'biopsy following 90-days of apalutamide.', 'Secondary Endpoints:', '1. Exit from active surveillance due to pathologic reclassification at 2 years.', '2. Exit from active surveillance for any reason at 2 years.', '3. Local treatment (e.g., radical prostatectomy, radiation therapy, brachytherapy) at 2 years', 'and the local treatment free survival.', '4. PSA progression and PSA progression free survival (PFS), as defined by the Prostate', 'Cancer Working Group 2 (PCWG2) criteria [Scher et al, 2008].', '5.', 'Radiographic disappearance of MRI detectable prostate cancer following treatment (in', 'patients with a baseline nodule that is PIRADS 3 or more and >5mm).', '6. Safety of apalutamide in men undergoing active surveillance.', 'a. Safety will be evaluated by the incidence, severity, duration, causality, seriousness,', 'and type(s) of adverse events as assessed by the revised National Cancer Institute', 'Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03', 'published 14 June 2010.', '7. Quality of life as assessed using the FACT-P and SF36 surveys.', '8. Exploratory biomarkers assessment. Examples of these may include, but are not limited to:', 'assessment for genomic PTEN loss via fluorescence in situ hybridization (FISH), PTEN', 'immunohistochemistry (IHC), assessment for alteration in MYC/chromosome 8q24 via FISH', 'and tumor mRNA expression profiling/risk classification (e.g., Decipher, Oncotype DX', 'Prostate Cancer Assay, or RNA-seq).', '7', 'Printed on 1/29/2021']\n\n###\n\n", "completion": "END"}